



02-20-07

1614

Express Mail No.: EV473971245US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: 9771

Application No.: 10/534,325

Group Art Unit: 1614

Filed: May 5, 2005

Examiner: Gembeh, Shirley V

For: **METHODS AND COMPOSITIONS USING
SELECTIVE CYTOKINE INHIBITORY
DRUGS FOR THE TREATMENT AND
MANAGEMENT OF CANCERS AND
OTHER DISEASES**

Attorney Docket No.: 9516-207-999

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to reference **C74** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." A copy of reference **C74** is provided herewith.


Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), Applicant estimates that a fee of \$180 is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge any necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: February 16, 2007



(Reg. No.)

By: Yeah-Sil Moon 52,042
For: Anthony M. Insogna 35,203
JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939



Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	9516-207-999	10/534,325
	APPLICANT:	
	Zeldis	
FILING DATE:	ART UNIT: CONF. NO.:	
May 5, 2005	1614 9771	

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO

NON PATENT LITERATURE DOCUMENTS (*include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s)s, volume, publisher, city and/or country where published., etc.)*)

EXAMINER'S INITIALS*	C74	BAATZ, H.; TONESSEN, B.; PRADA, J.; PLEYER, U.; Thalidomide Inhibits Leukocyte-Endothelium Interaction in Endotoxin-Induced Uveitis, Ophthalmic Research, 2001;33:256-263.
----------------------	-----	--

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.